Compare JD.Com Inc (JD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs TG Therapeutics Inc — how do they compare? JD.Com Inc trades at $27.09 (market cap $36.62B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: JD.Com Inc is far larger — about 4.5× TG Therapeutics Inc's market cap, and JD.Com Inc pays a 3.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and TG Therapeutics Inc for 16 Days on average.
| JD | TGTX | |
|---|---|---|
Market Cap | $36.62B | $8.16B |
Volume | 6,571,477 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $59.06 |
52-Week Low | $25.19 | $26.94 |
Typical Hold Time | 85 Days | 16 Days |
Enterprise Value | $19.26B | $8.37B |
Dividend Yield | 3.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.91, down 0.44% on the day, with a bullish technical signal despite mixed moving average indicators. The company shows strong fundamentals with revenue growth to $1.31 trillion in 2025 and consistent earnings beats, though net margins compressed to 1.13%. Recent news highlights JD's potential EU approval for its $2.5 billion Ceconomy acquisition and positive analyst sentiment with 69.6% buy ratings.
JD presents a compelling value opportunity with attractive valuation multiples (P/E 17.9, P/S 0.2) and strong cash position ($234B), though investors face risks from regulatory scrutiny and competitive pressures in China's e-commerce sector. The consensus price target of $35.86 suggests 33% upside potential from current levels.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
